Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398908 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL119530 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7532853 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29400620 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30291728 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29867802 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1044856 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7420121 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29382791 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1000115 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| CN-117377759-A | Self-purified nucleic acid-encoded libraries | 约尔格·谢尔曼 | 2024-01-09 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11702452-B2 | Process for making arylomycin ring analogs | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2021-10-21 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5872146-A | Mercapto alkyl peptidyl compounds having MMP and TNF inhibitory activity | CHIROSCIENCE LIMITED (GB) | 1999-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322381-A1 | DRUG FOR TREATMENT OR PREVENTION OF BLOOD CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, TIMP3 | TLR2 4456/4885MDM4 4844/4885TP53 3440/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | TLR2 3821/4885MDM4 441/4885TP53 34/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | TLR2 4530/4885MDM4 2123/4885TP53 85/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | TLR2 3406/4885MDM4 4652/4885TP53 4749/4885 |
| US-11702452-B2 | Process for making arylomycin ring analogs | RRS1, GLRA1, MRPL21 | TLR2 1136/4885MDM4 3039/4885TP53 2740/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | TLR2 20/4885MDM4 2087/4885TP53 2126/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TLR2 3866/4885MDM4 1648/4885TP53 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.